Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947744560> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2947744560 abstract "e16016 Background: Prior analyses demonstrated worse outcomes with the BP mUC clinical phenotype. UC molecular subtypes that may correlate with the BP phenotype have been defined, however molecular subtyping is not a readily available standard practice. We hypothesized that BP mUC has worse prognosis vs. non-BP (NBP) mUC and evaluated patient (pt) characteristics associated with the mUC subtype, responses and outcomes. Methods: We searched the electronic medical record (EMR) to identify pts with mUC who received systemic therapy in the metastatic setting. Demographic, clinicopathologic, treatment (trt), response, progression-free survival (PFS), overall survival (OS ) from start of first line trt. Imaging was reviewed to identify NBP or BP disease. Logistic regression, Cox proportional-hazards and Kaplan-Meier analyses were performed. Results: 149 mUC pts were identified (64% male, 68% smokers ), median age at 1 st line trt was 68 years. 70% had de-novo mets, 46% to lung and 27% to liver. 22% of pts were BP, of these, 36% were de-novo metastatic. In non- de-novo metastatic pts (70% of pts), first progression of disease to bone was associated with development of the BP phenotype (OR = 30.46, 95% CI 6.37 to 145.61; p < 0.0001). BP pts had higher rate of death (HR = 2.28, 95% CI 1.45 to 3.58, p = 0.0004), shorter PFS from 1 st line trt, (11.7 vs 14.9 weeks, p = 0.032) as well as shorter OS from 1 st line trt (24.6 vs 56.6 weeks, p = 0.002) compared to NBP pts. There was no difference in PFS between BP and NBP groups for pts treated with 1 st line platinum-based chemotherapy (11.8 vs 18.3 weeks, p = 0.091) or for BP pts treated with 1 st line immunotherapy vs platinum-based chemotherapy (11.71 vs 11.86 weeks, p = 0.135). Conclusions: Early bone metastases are associated with the development of the BP metastatic phenotype. BP pts have worse PFS and OS from 1st line trt compared to NBP pts. PFS remains poor when BP pts are treated with either platinum-based chemotherapy or immunotherapy in the first line setting. Imaging to determine the presence of bone metastases may routinely be pursued and careful attention paid on follow up imaging. Clinical trials and prospective registries focusing on efficacy endpoints for BP mUC are needed." @default.
- W2947744560 created "2019-06-07" @default.
- W2947744560 creator A5009444072 @default.
- W2947744560 creator A5011367118 @default.
- W2947744560 creator A5026717218 @default.
- W2947744560 creator A5037449345 @default.
- W2947744560 creator A5042184224 @default.
- W2947744560 creator A5055915139 @default.
- W2947744560 creator A5058267733 @default.
- W2947744560 creator A5058441653 @default.
- W2947744560 creator A5060963003 @default.
- W2947744560 creator A5062453358 @default.
- W2947744560 creator A5070016877 @default.
- W2947744560 creator A5076638739 @default.
- W2947744560 creator A5080126509 @default.
- W2947744560 creator A5088645680 @default.
- W2947744560 date "2019-05-20" @default.
- W2947744560 modified "2023-09-27" @default.
- W2947744560 title "Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype." @default.
- W2947744560 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e16016" @default.
- W2947744560 hasPublicationYear "2019" @default.
- W2947744560 type Work @default.
- W2947744560 sameAs 2947744560 @default.
- W2947744560 citedByCount "0" @default.
- W2947744560 crossrefType "journal-article" @default.
- W2947744560 hasAuthorship W2947744560A5009444072 @default.
- W2947744560 hasAuthorship W2947744560A5011367118 @default.
- W2947744560 hasAuthorship W2947744560A5026717218 @default.
- W2947744560 hasAuthorship W2947744560A5037449345 @default.
- W2947744560 hasAuthorship W2947744560A5042184224 @default.
- W2947744560 hasAuthorship W2947744560A5055915139 @default.
- W2947744560 hasAuthorship W2947744560A5058267733 @default.
- W2947744560 hasAuthorship W2947744560A5058441653 @default.
- W2947744560 hasAuthorship W2947744560A5060963003 @default.
- W2947744560 hasAuthorship W2947744560A5062453358 @default.
- W2947744560 hasAuthorship W2947744560A5070016877 @default.
- W2947744560 hasAuthorship W2947744560A5076638739 @default.
- W2947744560 hasAuthorship W2947744560A5080126509 @default.
- W2947744560 hasAuthorship W2947744560A5088645680 @default.
- W2947744560 hasConcept C104317684 @default.
- W2947744560 hasConcept C121608353 @default.
- W2947744560 hasConcept C126322002 @default.
- W2947744560 hasConcept C127716648 @default.
- W2947744560 hasConcept C142724271 @default.
- W2947744560 hasConcept C143998085 @default.
- W2947744560 hasConcept C2777783956 @default.
- W2947744560 hasConcept C2779013556 @default.
- W2947744560 hasConcept C2780352672 @default.
- W2947744560 hasConcept C2911057145 @default.
- W2947744560 hasConcept C3019882237 @default.
- W2947744560 hasConcept C502942594 @default.
- W2947744560 hasConcept C55493867 @default.
- W2947744560 hasConcept C71924100 @default.
- W2947744560 hasConcept C86803240 @default.
- W2947744560 hasConceptScore W2947744560C104317684 @default.
- W2947744560 hasConceptScore W2947744560C121608353 @default.
- W2947744560 hasConceptScore W2947744560C126322002 @default.
- W2947744560 hasConceptScore W2947744560C127716648 @default.
- W2947744560 hasConceptScore W2947744560C142724271 @default.
- W2947744560 hasConceptScore W2947744560C143998085 @default.
- W2947744560 hasConceptScore W2947744560C2777783956 @default.
- W2947744560 hasConceptScore W2947744560C2779013556 @default.
- W2947744560 hasConceptScore W2947744560C2780352672 @default.
- W2947744560 hasConceptScore W2947744560C2911057145 @default.
- W2947744560 hasConceptScore W2947744560C3019882237 @default.
- W2947744560 hasConceptScore W2947744560C502942594 @default.
- W2947744560 hasConceptScore W2947744560C55493867 @default.
- W2947744560 hasConceptScore W2947744560C71924100 @default.
- W2947744560 hasConceptScore W2947744560C86803240 @default.
- W2947744560 hasLocation W29477445601 @default.
- W2947744560 hasOpenAccess W2947744560 @default.
- W2947744560 hasPrimaryLocation W29477445601 @default.
- W2947744560 hasRelatedWork W1051443432 @default.
- W2947744560 hasRelatedWork W1520183139 @default.
- W2947744560 hasRelatedWork W1562392195 @default.
- W2947744560 hasRelatedWork W1989663680 @default.
- W2947744560 hasRelatedWork W1993826355 @default.
- W2947744560 hasRelatedWork W2015547025 @default.
- W2947744560 hasRelatedWork W2083424116 @default.
- W2947744560 hasRelatedWork W2148094738 @default.
- W2947744560 hasRelatedWork W2406145545 @default.
- W2947744560 hasRelatedWork W2476973162 @default.
- W2947744560 hasRelatedWork W2593410254 @default.
- W2947744560 hasRelatedWork W2621286113 @default.
- W2947744560 hasRelatedWork W2636744813 @default.
- W2947744560 hasRelatedWork W2942187418 @default.
- W2947744560 hasRelatedWork W3024459791 @default.
- W2947744560 hasRelatedWork W3029852375 @default.
- W2947744560 hasRelatedWork W3029857905 @default.
- W2947744560 hasRelatedWork W3031135592 @default.
- W2947744560 hasRelatedWork W3171721508 @default.
- W2947744560 hasRelatedWork W2555765778 @default.
- W2947744560 isParatext "false" @default.
- W2947744560 isRetracted "false" @default.
- W2947744560 magId "2947744560" @default.
- W2947744560 workType "article" @default.